Project Grant R21AI193429
Award Date
7/7/25
Completion Date
6/30/27
Dollars Obligated
$462K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $244,440.00 to Albert Einstein College of Medicine to conduct research on the role of cytolytic ZEB2+ memory CD4+ T cells in protection against liver stage malaria. The research aims to gain insights into the cellular immune determinants associated with natural clinical immunity to malaria, in order to inform the development of more effective...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $440,700.00 to New York University School of Medicine to conduct research focused on improving HIV vaccine design. The key goals are to: 1) Design and validate an immunogen targeting the V2B neutralization epitope on the HIV/SIV viral spike, and 2) Test the combination of vaccine-elicited anti-V2B...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), will support research to identify and characterize the specific proteins secreted by the ESX5 transport system in Mycobacterium tuberculosis, the causative agent of tuberculosis (TB). The $820,246 award to the Albert Einstein College of Medicine will be used to investigate the roles of these secreted proteins in...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $843,620 to Albert Einstein College of Medicine to develop broadly protective human monoclonal antibody therapies against alphaviruses. The key goals are to: 1) engineer Fc mutations to enhance the in vitro and in vivo properties of broadly neutralizing antibodies, 2) perform viral escape studies to define mechanisms...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $244,440 to the Albert Einstein College of Medicine to investigate the mechanisms by which LY6C+ monocytes respond to and help clear microbial pathogen infections. The research aims to define the chemotactic cues, receptors, and molecular processes involved in how these monocytes home to infection sites and form stable...
This federal Project Grant award for $246,623.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research at New York University School of Medicine to study the molecular control of tolerogenic dendritic cell function. The research aims to characterize the dendritic cell subset responsible for maintaining T cell tolerance, including investigating aberrant cytokine...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $13,946,446 Cooperative Agreement titled "PROVIDENT: PREPOSITIONING OPTIMIZED STRATEGIES FOR VACCINES AND IMMUNOTHERAPEUTICS AGAINST DIVERSE EMERGING INFECTIOUS THREATS" to the Albert Einstein College of Medicine. The overarching goal of this 5-year project is to deliver "plug-and-play" vaccine and therapeutic antibody...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $910,905.00 to the Scripps Research Institute to advance HIV vaccine development using a lipid nanodisc platform. The key objectives are to: Solve the structures of engineered transmembrane HIV envelope (Env) proteins incorporated into lipid nanodiscs in complex with broadly neutralizing antibodies targeting the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $693,465 to Cornell University over a period from January 2025 to December 2029. The funding supports a research project titled "Mapping Infant and Adult T Cell Immunity" that aims to construct a molecular atlas of T cell development in lymph nodes and determine how cellular interactions and communication networks change during CD8+ T...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to elucidate the molecular mechanisms underlying T cell dysfunction and HIV persistence in persons with HIV (PWH). The $500,000 award, effective from September 1, 2024 to August 31, 2029, will support research conducted by The General Hospital Corporation (Massachusetts General Hospital) to identify and...